human
coronavirus
hcov
enter
cell
via
two
distinct
pathway
endosom
pathway
use
cathepsin
activ
spike
protein
cellsurfac
earli
endosom
pathway
use
extracellular
proteas
transmembran
proteas
serin
previous
report
clinic
isol
prefer
cellsurfac
endosom
cathepsin
cell
entri
acquir
abil
use
cathepsin
l
repeat
passag
cultur
cell
abl
enter
cell
via
endosom
pathway
show
clinic
isol
prefer
cellsurfac
endosom
cathepsin
cell
entri
similar
addit
cellcultureadapt
lost
abil
infect
replic
airliquid
interfac
cultur
human
bronchial
tracheal
epitheli
cell
result
suggest
circul
hcov
field
gener
use
cellsurfac
cell
entri
endosom
cathepsin
human
airway
epitheli
cell
human
coronavirus
hcov
caus
agent
human
common
cold
peopl
experi
initi
infect
childhood
dijkman
et
al
date
four
hcov
identifi
first
two
belong
alphacoronaviru
latter
two
betacoronaviru
first
report
hamr
procknow
isol
day
wide
use
laboratori
strain
american
type
cultur
collect
atcc
enter
cell
via
two
distinct
pathway
endosom
pathway
use
cystein
proteas
activ
spike
protein
cellsurfac
earli
endosom
pathway
use
extracellular
proteas
activ
studi
use
atcc
isol
suggest
enter
cell
via
late
endosom
use
cathepsin
l
cleav
protein
although
enter
cell
via
cell
surfac
earli
endosom
presenc
transmembran
proteas
serin
trypsin
bertram
et
al
kawas
et
al
thought
gener
featur
entri
howev
recent
report
clinic
isol
prefer
cellsurfac
earli
endosom
pathway
late
endosom
pathway
cell
entri
shirato
et
al
abil
clinic
isol
use
cathepsin
l
origin
low
becam
abl
use
cathepsin
repeat
passag
hela
cell
shirato
et
al
suggest
natur
situat
enter
respiratori
epitheli
cell
via
cellsurfac
earli
endosom
rout
charact
atcc
chang
repeat
passag
cultur
cell
recent
year
cultur
method
human
bronchial
tracheal
epitheli
hbte
cell
use
airliquid
interfac
ali
develop
come
use
model
vivo
situat
human
airway
epithelium
hae
fulcher
et
al
use
system
previous
report
sequenc
data
first
isol
pyrc
et
al
later
shown
four
hcov
could
isol
upon
hbteali
cell
cultur
present
studi
found
field
isol
could
isol
use
hbteali
cell
cultur
use
clinic
isol
assess
whether
mode
viru
entri
found
also
play
hcov
isol
hcov
nasal
swab
collect
outpati
show
respiratori
infect
cardin
symptom
assess
hospit
tokyo
japan
specimen
diagnos
contain
hcov
realtim
rtpcr
use
viru
isol
recent
circul
hcov
strain
japan
bias
toward
hara
takao
matoba
et
al
yano
et
al
therefor
obtain
specimen
posit
howev
four
two
isol
final
isol
success
tabl
sequenc
protein
analyz
deposit
genbank
access
no
number
cycl
realtim
rtpcr
virusisol
specimen
subject
rang
isol
consid
fail
cycl
use
data
shown
suggest
least
copi
viral
rna
requir
success
isol
hbteali
cultur
similar
identifi
late
bruckova
et
al
mcintosh
et
al
mcintosh
et
al
isol
time
pass
suckl
mous
brain
cell
cultur
final
becam
wide
use
laboratori
strain
atcc
previous
describ
entri
mechan
clinic
isol
differ
cellcultureadapt
laboratori
isol
clinic
isol
prefer
cellsurfac
rout
endosom
cathepsin
rout
prefer
atcc
isol
shirato
et
al
therefor
evalu
differ
infect
replic
cultur
cell
hbteali
cultur
use
clinic
isol
fig
cell
infect
replic
well
expect
hand
amount
viru
enter
cell
much
lower
amount
replic
lower
fig
hbteali
cultur
result
complet
revers
infect
cell
replic
well
expect
contrast
could
infect
hbteali
cultur
though
amount
enter
viru
much
lower
compar
viral
rna
detect
cell
wash
day
infect
fig
indic
infect
hbteali
cultur
low
effici
fail
produc
progeni
viru
previou
report
clinic
isol
exhibit
chang
allow
replic
well
hela
cell
abil
replic
hbteali
cultur
decreas
rel
origin
isol
shirato
et
al
present
studi
indic
phenomenon
seen
also
present
name
cellcultureadapt
viru
replic
hbteali
cultur
mimic
human
airway
epitheli
cell
case
clinic
isol
enter
cell
via
cellsurfac
earli
endosom
rout
use
atcc
isol
tend
enter
cell
via
late
endosom
pathway
use
cathepsin
l
bertram
et
al
kawas
et
al
shirato
et
al
former
rout
inhibit
serin
proteas
inhibitor
camostat
latter
cystein
proteas
inhibitor
est
shirato
et
al
shirato
et
al
evalu
entri
rout
clinic
isol
hcov
virus
inocul
onto
hbteali
presenc
est
camostat
amount
viru
enter
estim
detect
subgenom
mrna
use
realtim
rtpcr
fig
first
effect
inhibitor
treatment
cell
viabil
determin
cell
treatment
affect
surviv
cell
cultur
concentr
fig
infect
inhibit
est
camostat
fig
indic
enter
cell
via
late
endosom
pathway
use
cystein
proteas
use
cell
entri
hbteali
cultur
contrast
clinic
isol
inhibit
camostat
either
inhibit
partial
inhibit
est
fig
case
est
increas
entri
fig
clinic
isol
similar
entri
inhibit
camostat
est
tend
increas
entri
fig
h
shown
fig
treatment
inhibitor
affect
cell
viabil
suggest
reduc
infect
est
clinic
isol
camostat
induc
inhibit
proteas
k
shirato
et
al
virolog
inhibitor
treatment
data
ident
deriv
use
shirato
et
al
suggest
clinic
isol
hcov
caus
human
infect
enter
cell
via
cellsurfac
earli
endosom
pathway
use
cellsurfac
proteas
data
also
suggest
entri
cell
via
late
endosom
use
cathepsin
case
cellcultureadapt
longtermpassag
isol
hcov
moreov
increas
entri
clinic
isol
presenc
est
suggest
entri
cell
via
late
endosom
pathway
induc
antivir
host
immun
express
hbteali
cultur
confirm
mrna
quantit
fig
express
mrna
found
lovo
cell
known
suscept
middl
east
respiratori
syndrom
mer
coronaviru
shirato
et
al
tao
et
al
express
highli
upregul
promin
among
cell
test
differenti
hbteali
cultur
cell
mrna
detect
express
level
lower
immatur
hbte
cell
almost
detect
hela
cell
suggest
reduc
infect
replic
clinic
isol
cell
caus
low
level
express
rel
hbteali
cultur
cathepsin
use
entri
cell
confirm
entri
inhibit
assay
similar
hbteali
cultur
fig
c
entri
inhibit
est
treatment
fig
infect
high
concentr
est
inhibit
entri
fig
contrast
camostat
treatment
show
inhibit
term
infect
howev
hct
k
shirato
et
al
virolog
cell
express
mrna
find
suggest
express
cell
insuffici
entri
cell
surfac
also
suggest
cathepsin
use
entri
cell
mani
year
isol
hcov
consid
difficult
peiri
poon
tyrrel
myint
first
isol
report
use
repeat
passag
cultur
cell
suckl
mous
brain
bruckova
et
al
hamr
procknow
mcintosh
et
al
mcintosh
et
al
later
studi
report
isol
hcov
use
llcmk
cell
monkey
kidney
cell
human
embryo
fibroblast
van
der
hoek
et
al
group
other
report
addit
extern
proteas
trypsin
transmembran
serin
proteas
enhanc
entri
replic
hcov
bertram
et
al
kawas
et
al
kawas
et
al
addit
proteas
result
success
isol
hirokawa
et
al
matoba
et
al
howev
reliabl
cell
line
isol
avail
unlik
exampl
mdck
cell
use
isol
influenza
virus
result
present
studi
show
report
difficulti
isol
hcov
natur
phenomenon
hcov
circul
natur
world
enter
cell
via
late
endosom
pathway
use
cathepsin
difficult
virus
grow
commonli
use
cultur
cell
late
endosom
pathway
date
hcov
isol
use
cell
cultur
describ
may
result
rather
accident
sometim
particular
featur
cultur
cell
may
affect
result
time
quasispeci
may
select
abil
use
cathepsin
cell
entri
forc
select
inde
produc
hcov
charact
virus
chang
natur
state
studi
inhibit
late
endosom
pathway
est
increas
entri
clinic
viru
isol
suggest
cell
entri
via
late
endosom
pathway
induc
antivir
host
immun
inde
bertram
et
al
report
express
interferoninduc
transmembran
protein
ifitm
inhibit
divers
envelop
virus
also
inhibit
entri
pseudotyp
viru
bear
protein
reduc
entri
rescu
coexpress
thought
ifitm
exert
antivir
effect
late
stage
entri
desai
et
al
li
et
al
munozmoreno
et
al
thu
enter
cell
via
endosom
cathepsin
seem
afford
advantag
viru
surviv
therefor
hcov
circul
field
may
evolv
use
late
endosom
rout
cathepsin
avoid
unfavor
reaction
host
cell
addit
use
cathepsin
entri
cultur
cell
line
howev
studi
est
treatment
could
inhibit
viral
entri
complet
even
high
concentr
previous
report
sirnamedi
gene
knockdown
cathepsin
l
could
inhibit
entri
complet
suggest
proteas
also
use
process
infect
kawas
et
al
moreov
treatment
est
camostat
leupeptin
cell
human
fetal
pulmonari
fibroblast
without
express
inhibit
infect
merscov
suggest
proteas
cystein
serin
threonin
might
use
entri
immatur
cell
shirato
et
al
therefor
although
cathepsin
use
entri
process
cell
proteas
cathepsin
also
use
activ
protein
like
human
coronavirus
develop
hbteali
cell
cultur
method
allow
success
isol
hcov
probabl
natur
state
pyrc
et
al
develop
antivir
drug
necessari
understand
viru
characterist
isol
viru
first
step
therefor
import
isol
viru
natur
characterist
madu
et
al
report
common
motif
highli
conserv
region
vhcr
found
protein
coronaviru
may
possibl
fusion
peptid
thought
recognit
site
cleavabl
proteas
might
exist
around
fusion
peptid
previou
studi
show
two
amino
acid
differ
laboratori
clinic
isol
determin
differ
cell
entri
rout
sandwich
vhcr
therefor
thought
proteas
recognit
site
howev
substitut
two
amino
acid
laboratori
clinic
isol
complet
chang
invert
cathepsin
l
use
cell
entri
shirato
et
al
impli
structur
modif
protein
caus
two
amino
acid
mutat
affect
access
cathepsin
l
true
recognit
site
shown
fig
two
remark
amino
acid
differ
seen
laboratori
clinic
isol
mutat
furin
recognit
site
may
affect
sensit
furin
park
et
al
report
mer
coronaviru
differ
entri
process
depend
whether
protein
cleav
furin
protein
cleav
furin
cell
entri
entri
sensit
cellsurfac
proteas
mer
enter
cell
earli
endosom
yet
viru
uncleav
protein
traffick
cellsurfac
proteas
late
endosom
also
report
uncleav
virus
less
infecti
human
airway
epitheli
cell
cultur
park
et
al
inde
clinic
isol
retain
furin
cleavag
site
fig
data
studi
show
infect
depend
express
idea
support
find
studi
clinic
isol
cleav
protein
select
cellsurfac
rout
entri
sensit
cleavag
cell
surfac
proteas
thu
although
mutat
furin
site
may
affect
use
cellsurfac
proteas
two
mutat
sandwich
vhcr
similar
report
previous
adapt
cell
cultur
alter
proteas
sensit
protein
cathepsin
l
shirato
et
al
addit
studi
requir
elucid
role
mutat
protein
infect
event
show
clinic
isol
prefer
cellsurfac
endosom
cathepsin
cell
entri
addit
cellcultureadapt
lost
abil
infect
replic
hbteali
cell
cultur
mimic
natur
situat
hae
result
indic
clinic
isol
hcov
field
gener
enter
cell
via
late
endosom
cathepsin
via
cell
surfac
earli
endosom
addit
studi
suggest
viru
adapt
cultur
cell
isol
alter
rout
cell
entri
modifi
isol
might
reflect
hcov
natur
world
strain
obtain
atcc
propag
titrat
use
rd
cell
atcc
clinic
isol
isol
use
hbteali
cultur
nasal
swab
obtain
outpati
hospit
tokyo
japan
approv
nation
institut
infecti
diseas
ethic
review
board
human
subject
specimen
subject
respiratori
viru
test
realtim
rtpcr
kaida
et
al
hcovposit
specimen
inocul
onto
hbteali
cultur
h
incub
wash
dmem
twice
incub
incub
day
cell
wash
four
time
dmem
contain
vv
fetal
calf
serum
use
viru
stock
viru
replic
confirm
calcul
rna
copi
number
use
realtim
rtpcr
describ
earlier
dare
et
al
van
elden
et
al
compar
wash
viru
adsorpt
isol
virus
relev
rtpcr
result
list
tabl
sequenc
protein
obtain
use
sanger
method
align
analysi
perform
use
genedoc
softwar
http
wwwnrbscorggfxgenedocebinethtm
evalu
replic
kinet
clinic
atcc
isol
copi
viru
inocul
onto
hbteali
cultur
cell
incub
h
cell
wash
twice
incub
day
incub
cell
collect
use
analysi
viru
entri
cell
supernat
cell
wash
obtain
day
incub
use
evalu
viru
replic
describ
amount
replic
viru
express
rna
copi
number
cell
supernat
cell
wash
minu
remain
cell
wash
viru
adsorpt
entri
inhibit
assay
use
hbteali
cultur
copi
virus
inocul
onto
cell
pretreat
entri
inhibitor
est
ethyl
ester
calbiochem
san
diego
ca
usa
camostat
mesyl
tocri
bioscienc
bristol
uk
h
incub
h
presenc
inhibitor
cell
wash
twice
incub
day
incub
cell
collect
cell
viabil
determin
use
celltiterglo
glomax
luminomet
promega
madison
wi
usa
total
cellular
rna
extract
use
isogen
nippon
gene
tokyo
japan
ribonucl
acid
baker
yeast
sigma
carrier
rna
assess
viru
entri
subgenom
rna
contain
nucleocapsid
protein
amplifi
realtim
rtpcr
use
follow
primer
probe
set
forward
revers
probe
famlabel
forward
revers
probe
famlabel
rna
copi
number
calcul
standard
curv
obtain
aid
control
rna
templat
data
statist
analyz
use
unpair
ttest
present
log
rna
copi
per
well
express
level
mrna
examin
realtim
rtpcr
assay
total
rna
extract
trizol
thermo
fisher
scientif
waltham
usa
accord
manufactur
instruct
realtim
pcr
perform
use
fast
viru
master
mix
thermo
fisher
scientif
roch
basel
switzerland
commerci
specif
primer
use
follow
gapdh
thermo
fisher
scientif
thermo
fisher
scientif
data
present
rel
valu
calcul
base
gapdh
valu
cell
atcc
lovo
cell
jcrb
cell
bank
japan
use
posit
control
express
hela
cell
atcc
use
neg
control
